Back to Search
JAMES ENGELMAN, D.O.
D.O.
Physical Medicine & Rehabilitation Physician
NPI: 1528002110Individual
Specialties, Licenses & Credentials
Physical Medicine & Rehabilitation PhysicianPrimary
Physical Medicine & Rehabilitation
Code: 208100000X
25MB06769400(NJ)
Research & Publications (20)
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
PMID 19106609·Cell Cycle·2009
6-review
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
PMID 19629070·Nat Rev Cancer·2009
6-review
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
PMID 19447865·Clin Cancer Res·2009
7-preclinical
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
PMID 19237633·J Clin Oncol·2009
8-other
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
PMID 18458038·J Clin Oncol·2008
3-trial
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
PMID 18483355·Clin Cancer Res·2008
6-review
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
PMID 18568074·J Clin Invest·2008
7-preclinical
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.
PMID 18594010·Clin Cancer Res·2008
8-other
Modeling oncogene addiction using RNA interference.
PMID 18711136·Proc Natl Acad Sci U S A·2008
8-other
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
PMID 19029981·Nat Med·2008
7-preclinical
Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
PMID 18325754·Curr Opin Genet Dev·2008
6-review
The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer.
PMID 17671156·Clin Cancer Res·2007
6-review
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
PMID 17699871·Clin Cancer Res·2007
7-preclinical
Syphilis in the United States: an update for clinicians with an emphasis on HIV coinfection.
PMID 17803877·Mayo Clin Proc·2007
8-other
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
PMID 18089823·Cancer Res·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 901 W MAIN ST
FREEHOLD, NJ 07728 - Phone
- (732) 431-5024
Quick Facts
- NPI
- 1528002110
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile